Fanconi Anemia Clinical Trial
— MicroFancIIOfficial title:
Microcephaly, Fanconi Anemia and Praxial Disorders
Verified date | January 2023 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fanconi Anemia (FA) is mentioned in children with congenital malformations including kidney, hart and skeletal malformations (absence or abnormal thumb or forearm), and bone marrow failure or myelodysplasia with a progressive onset in childhood or adulthood. No study has focused on microcephaly, a reduction in brain volume, which is present in 20% of children, and its consequences on cognitive and structural level of the brain. Since 2014, Robert-Debré's team has been interested in this functional cognitive and neuroanatomical approach trough a National PHRC. Preliminary results carried out on 12 children show that their intellectual efficiency was in the normal range for age. However, we noticed a significant difference between abilities in comprehension and verbal reasoning corresponding to what is expected for age, and the sensorimotor skills or fine motor praxia significantly reduced. These difficulties, graphically penalizing for these children, are not always explained by a skeletal malformation of the upper limb, suggesting that musculo-tendinous anomalies may be associated. The objectives of our project are: 1) to identify upper limb musculo-tendinous abnormalities and their functional consequences, 2) to determine if these abnormalities could influence the somatosensory representation of the upper limb at the cerebral cortical level. This project should help us to better understand the fine motor disabilities or developmental coordination disorder of these children, which penalize their learning, and provide them with adapted solutions.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 30, 2023 |
Est. primary completion date | January 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 21 Years |
Eligibility | Inclusion Criteria: 1. Patients with Fanconi Anemia defined according to two of the following diagnostic criteria already included in the MicroFanc study: - Chromosome breakage test after exposure to an alkylating agent (mitomycin) on peripheral blood lymphocytes. - FancD2 test on lymphocytes or fibroblasts - sensitivity of fibroblasts to mitomycin - mutation in one of the FANC complementation genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N) 2. Non-transplanted patients or patients at a distance from CSH transplant (>3 years) 3. Age =5 years of age at inclusion (minimum age of accessibility for neuropsychological tests and no need for sedation for MRI) Exclusion Criteria: Subjects for whom both parents have not agreed to participate in the research, or for whom MRI is contraindicated. |
Country | Name | City | State |
---|---|---|---|
France | Robert Drbré Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measurement of fine motor praxia | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02931071 -
Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
|
Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT01146210 -
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
|
N/A | |
Completed |
NCT01082133 -
Multicenter Transplant Study for Fanconi Anemia
|
Phase 2 | |
Completed |
NCT00965666 -
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
|
Early Phase 1 | |
Terminated |
NCT00290628 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
N/A | |
Recruiting |
NCT00027274 -
Cancer in Inherited Bone Marrow Failure Syndromes
|
||
Terminated |
NCT01001598 -
Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
|
Phase 1/Phase 2 | |
Recruiting |
NCT03206086 -
Eltrombopag for People With Fanconi Anemia
|
Phase 2 | |
Recruiting |
NCT03579875 -
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
|
Phase 2 | |
Recruiting |
NCT05598515 -
Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia
|
N/A | |
Active, not recruiting |
NCT03476330 -
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
|
Phase 2 | |
Terminated |
NCT05910853 -
Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
|
||
Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT00479115 -
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
|
Phase 1/Phase 2 | |
Completed |
NCT00352976 -
TBI Dose De-escalation for Fanconi Anemia
|
Phase 2/Phase 3 | |
Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 |